Free tool
FAERS Monitor: Synarel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019886 or its brand name (Synarel, Nafarelin Acetate). Reports on generic versions are filed under their own applications.
Reports
273
Serious
225
82% of reports
Hospitalization
97
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome48
- dyspnoea19
- ascites18
- condition aggravated13
- diarrhoea13
- headache13
- nausea13
- off label use13
- pain13
- abdominal pain12
- drug ineffective11
- malaise11
- abortion spontaneous10
- fatigue10
- abdominal distension9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 34 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 10 |
| 2014 | 21 |
| 2015 | 13 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 14 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 13 |
| 2022 | 16 |
| 2023 | 14 |
| 2024 | 16 |
| 2025 | 15 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,886 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 48 | 1620.0 | 1249.0 | 74,499 |
| ascitesSignal | 18 | 47.2 | 30.2 | 769 |
| abortion spontaneousSignal | 10 | 19.2 | 10.5 | 155 |
| abdominal distensionSignal | 9 | 6.6 | 3.5 | 38 |
| abdominal painSignal | 12 | 4.0 | 2.3 | 24 |
| condition aggravatedSignal | 13 | 3.3 | 1.9 | 19 |
| dyspnoeaSignal | 19 | 2.6 | 1.7 | 17 |
| malaise | 11 | 1.9 | 1.1 | 4 |
| pain | 13 | 1.6 | 1.0 | 3 |
| headache | 13 | 1.6 | 0.9 | 2 |
| diarrhoea | 13 | 1.6 | 0.9 | 2 |
| nausea | 13 | 1.3 | 0.7 | 1 |
| off label use | 13 | 1.1 | 0.7 | 0 |
| fatigue | 10 | 1.0 | 0.5 | 0 |
| drug ineffective | 11 | 0.6 | 0.4 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.